A selective angiotensin receptor antagonist , Valsartan , produced regression of left ventricular hypertrophy associated with a reduction of arterial stiffness . 
<br>
<br> We investigated whether a selective angiotensin II receptor blocker ( ARB ) would have a regressive effect on left ventricular hypertrophy ( LVH ) in <font color="red">patients_2</font> <font color="red">on_2</font> <font color="red">continuous_2</font> <font color="red">ambulatory_2</font> <font color="red">peritoneal_2</font> <font color="red">dialysis_2</font> <font color="red">(_2</font> <font color="red">CAPD_2</font> <font color="red">)_2</font> <font color="red">._2</font> In a double - blind study , <font color="red">24_2</font> <font color="red">CAPD_2</font> <font color="red">patients_2</font> <font color="red">with_2</font> <font color="red">LVH_2</font> <font color="red">[_2</font> <font color="red">left_2</font> <font color="red">ventricular_2</font> <font color="red">mass_2</font> <font color="red">index_2</font> <font color="red">(_2</font> <font color="red">LVMi_2</font> <font color="red">)_2</font> <font color="red">>_2</font> <font color="red">110_2</font> <font color="red">g_2</font> <font color="red">/_2</font> <font color="red">m2_2</font> <font color="red">for_2</font> <font color="red">women_2</font> <font color="red">and_2</font> <font color="red">LVMi_2</font> <font color="red">>_2</font> <font color="red">137_2</font> <font color="red">g_2</font> <font color="red">/_2</font> <font color="red">m2_2</font> <font color="red">for_2</font> <font color="red">men_2</font> <font color="red">]_2</font> were randomized to 12 months ' administration of either the ARB valsartan ( n = 14 ) or a placebo ( n = 10 ) . <font color="red">The_1</font> <font color="red">target_1</font> <font color="red">blood_1</font> <font color="red">pressure_1</font> <font color="red">(_1</font> <font color="red">BP_1</font> <font color="red">)_1</font> <font color="red">was_1</font> <font color="red">140/90_1</font> <font color="red">mmHg_1</font> <font color="red">or_1</font> <font color="red">lower_1</font> <font color="red">in_1</font> <font color="red">both_1</font> <font color="red">groups_1</font> <font color="red">._1</font> The following parameters were measured before and at the end of the study : aortic and large - artery compliance and arterial wave reflections [ pulse wave velocity ( PWV ) and augmentation index ( AI ) application tonometry ] and cardiac echocardiography . Periodically recorded were body weight , BP ( mercury sphygmomanometer ) , serum creatinine , electrolytes , complete blood cell counts , urine volume , drainage volume , and weekly creatinine clearance . Two - way analysis of variance for repeated measurements was used for statistical analysis . Systolic and diastolic BP were both reduced in patients treated with ARB . The LVMi was significantly reduced in patients treated with ARB ( to 121 + /- 4 from 145 + /- 5 ) but not in those receiving placebo ( to 137 + /- 3 from 152 + /- 3 , p < 0.05 ) . The decrease in LVMi was associated with a reduction in PWV and AI . In <font color="red">CAPD_2</font> <font color="red">patients_2</font> <font color="red">with_1</font> <font color="red">LVH_1</font> <font color="red">,_1</font> ARB reduced LVMi in association with alterations in arterial hemodynamics .